Alphamab Oncology announced that Reference is made to the inside information announcement of the Company dated November 14, 2023. The Company wishes to provide further updates in relation to KN046-303, a multi-center, randomized, double-blind, placebo-controlled phase III clinical trial designed to evaluate the efficacy and safety of KN046 in combination with nab-paclitaxel/gemcitabine versus placebo in combination with nab-paclitaxel/gemcitabine, for the treatment of patients with locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC) without systemic treatment. The board (the "Board") of directors (the "Directors") of the Company announces that the preset number of death events for KN046-303 was reached.

Analysis indicates that the overall survival (OS) result did not reach the preset statistical endpoint.